Jon W. Henry

Array ( [id] => 11457150 [patent_doc_number] => 20170051055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'HUMAN ANTI-IFN-ALPHA ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/902409 [patent_app_country] => US [patent_app_date] => 2014-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 64 [patent_figures_cnt] => 64 [patent_no_of_words] => 46852 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14902409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11844590 [patent_doc_number] => 09732135 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-15 [patent_title] => 'Targeting of human interferon antagonists' [patent_app_type] => utility [patent_app_number] => 14/905348 [patent_app_country] => US [patent_app_date] => 2014-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 4961 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14905348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9844489 [patent_doc_number] => 08946406 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-03 [patent_title] => 'Derivatisation of erythropoietin (EPO)' [patent_app_type] => utility [patent_app_number] => 14/313897 [patent_app_country] => US [patent_app_date] => 2014-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 10687 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14313897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10906153 [patent_doc_number] => 20140309166 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-16 [patent_title] => 'Derivatisation of Erythropoietin (EPO)' [patent_app_type] => utility [patent_app_number] => 14/313888 [patent_app_country] => US [patent_app_date] => 2014-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 10684 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14313888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9823542 [patent_doc_number] => 08933026 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-01-13 [patent_title] => 'Derivatisation of erythropoietin (EPO)' [patent_app_type] => utility [patent_app_number] => 14/313870 [patent_app_country] => US [patent_app_date] => 2014-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 10686 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14313870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10905693 [patent_doc_number] => 20140308706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-16 [patent_title] => 'RECOMBINANT FUSION INTERFERON FOR ANIMALS' [patent_app_type] => utility [patent_app_number] => 14/306808 [patent_app_country] => US [patent_app_date] => 2014-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6394 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14306808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9756199 [patent_doc_number] => 20140286901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-25 [patent_title] => 'Methods, Pharmaceutical Compositions and Kits for Use in the Treatment of Adult T-Cell Leukemia/Lymphoma' [patent_app_type] => utility [patent_app_number] => 14/301756 [patent_app_country] => US [patent_app_date] => 2014-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8565 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14301756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10255002 [patent_doc_number] => 20150139999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-21 [patent_title] => 'INTERFERON ANTAGONISTS, ANTIBODIES THERETO, AND ASSOCIATED METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/297086 [patent_app_country] => US [patent_app_date] => 2014-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 31813 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14297086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10769087 [patent_doc_number] => 20160115242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-28 [patent_title] => 'ANTI-CSPG4 FUSIONS WITH INTERFERON FOR THE TREATMENT OF MALIGNANCY' [patent_app_type] => utility [patent_app_number] => 14/893912 [patent_app_country] => US [patent_app_date] => 2014-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 35406 [patent_no_of_claims] => 141 [patent_no_of_ind_claims] => 42 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14893912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10761964 [patent_doc_number] => 20160108117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-21 [patent_title] => 'Anti-CXCL1, CXCL7 and CXCL8 Antibodies and their Applications' [patent_app_type] => utility [patent_app_number] => 14/891833 [patent_app_country] => US [patent_app_date] => 2014-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 24929 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14891833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11685956 [patent_doc_number] => 09683999 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-20 [patent_title] => 'Diagnostic blood test for sarcoidosis' [patent_app_type] => utility [patent_app_number] => 14/279591 [patent_app_country] => US [patent_app_date] => 2014-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 8586 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 225 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14279591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11536926 [patent_doc_number] => 09611322 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-04 [patent_title] => 'Fusions of antibodies to CD38 and attenuated interferon alpha' [patent_app_type] => utility [patent_app_number] => 14/262841 [patent_app_country] => US [patent_app_date] => 2014-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 63 [patent_no_of_words] => 52939 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14262841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10738700 [patent_doc_number] => 20160084851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-24 [patent_title] => 'NOVEL BIOMARKERS' [patent_app_type] => utility [patent_app_number] => 14/786173 [patent_app_country] => US [patent_app_date] => 2014-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8456 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14786173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10755990 [patent_doc_number] => 20160102142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-14 [patent_title] => 'Antibodies Targeting M-CSF' [patent_app_type] => utility [patent_app_number] => 14/781601 [patent_app_country] => US [patent_app_date] => 2014-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 13150 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14781601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16168222 [patent_doc_number] => 10709762 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-14 [patent_title] => Use of M-CSF for preventing or treating myeloid cytopenia and related complications [patent_app_type] => utility [patent_app_number] => 14/782612 [patent_app_country] => US [patent_app_date] => 2014-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 16861 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14782612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9634275 [patent_doc_number] => 20140212383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-31 [patent_title] => 'SUPPRESSOR OF THE ENDOGENOUS INTERFERON-GAMMA' [patent_app_type] => utility [patent_app_number] => 14/243861 [patent_app_country] => US [patent_app_date] => 2014-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11515 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14243861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13065453 [patent_doc_number] => 10053499 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-21 [patent_title] => Polypeptide having sialylated sugar chains attached thereto [patent_app_type] => utility [patent_app_number] => 14/780133 [patent_app_country] => US [patent_app_date] => 2014-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 24740 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14780133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9771184 [patent_doc_number] => 20140294848 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-02 [patent_title] => 'Novel Targets for Regulation of Angiogenesis' [patent_app_type] => utility [patent_app_number] => 14/222926 [patent_app_country] => US [patent_app_date] => 2014-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 37461 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14222926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9698580 [patent_doc_number] => 20140248265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-04 [patent_title] => 'THERAPEUTIC ANTIBODIES BINDING IL 12RBETA1' [patent_app_type] => utility [patent_app_number] => 14/220166 [patent_app_country] => US [patent_app_date] => 2014-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30557 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14220166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12199714 [patent_doc_number] => 09902770 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-27 [patent_title] => 'Interferon alpha and omega antibody antagonists' [patent_app_type] => utility [patent_app_number] => 14/208861 [patent_app_country] => US [patent_app_date] => 2014-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 21416 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14208861 [rel_patent_id] =>[rel_patent_doc_number] =>)